Fig. 2: Kaplan–Meier analysis of OS in the HR+ and HR− cohorts. | Nature Medicine

Fig. 2: Kaplan–Meier analysis of OS in the HR+ and HR− cohorts.

From: Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial

Fig. 2

a,b, HR+ cohort (a) and HR− cohort (b). For the OS and PFS by investigator endpoints for the HR+ and all patient cohorts, the HR status is based on data collected using the interactive web-response and voice-response system at the time of randomization, which includes patients who were misstratified. The dashed lines depict the landmark OS rates at 24 and 36 months.

Back to article page